NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk ...
That would be an impressive run if it could get there soon.
Zacks Investment Research on MSN
Is it worth investing in Viking Therapeutics (VKTX) based on Wall Street's bullish views?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...
Zacks Investment Research on MSN
Viking Therapeutics, Inc. (VKTX) sees a more significant dip than broader market: Some facts to know
Viking Therapeutics, Inc. (VKTX) ended the recent trading session at $37.48, demonstrating a -3.92% change from the preceding day's closing price. The stock's change was less than the S&P 500's daily ...
Data readout from the maintenance dosing study of VK2735, the company’s investigational obesity candidate, is expected in the ...
Viking Therapeutics (NasdaqCM:VKTX) has begun a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor ...
Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...
Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in General Motors Co (Symbol: GM), where a total of 73,915 contracts have traded so far, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results